Innate Pharma S.A. (IPHYF) Research

Innate Pharma S.A., a biotechnology firm based in Marseille, France, operates globally, focusing on the discovery, advancement, and commercialization of innovative antibody-based therapies, primarily targeting various oncological conditions. The company's clinical pipeline includes several promising candidates: Lacutamab (IPH4102): An anti-KIR3DL2 antibody currently undergoing Phase II clinical evaluation for cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor that has progressed to Phase III clinical trials, being investigated for its potential in treating advanced solid tumors, notably colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1. This compound is in Phase II clinical assessment for a range of inflammatory conditions, including COVID-19, bullous pemphigoid, and chronic spontaneous urticaria. IPH5201: A blocking antibody in Phase I trials, aimed at the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody targeting the immunosuppressive adenosine pathway to enhance anti-tumor immunity. IPH6101: An NKp46-based NK cell engager, intended for the development and assessment of up to two bispecific NK cell engagers. Beyond its clinical programs, Innate Pharma maintains an active preclinical research effort, featuring candidates such as IPH43 (an anti-MICA/B antibody-drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. To support its development and market reach, Innate Pharma has established strategic alliances and licensing agreements with major pharmaceutical companies, including AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Additionally, it holds a co-development and license agreement with MedImmune Limited. The company was founded in 1999 and continues to operate from its headquarters in Marseille, France.

Open Innate Pharma S.A. (IPHYF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.